These include the monoclonal antibodies trastuzumab and pertuzumab, which are currently the first line of treatment for HER2-positive breast cancers, and the antibody-drug conjugate (ADC) T-DM1, as the second line [2,3]. The gene discussed is ERBB2; the disease is breast cancer.